NCT02149940已完成不适用
Feasibility of Pharmaceutical Interventions in Elderly Heart Failure Patients: a Pilot Study.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 29
- 试验地点
- 2
- 主要终点
- the number of heart-failure related pharmaceutical interventions
研究概览
简要总结
Heart failure therapies (e.g. beta blockers) have been successful in decreasing mortality rates, as well as diminishing hospitalizations. Also, pharmacist collaboration has been shown to have a beneficial impact on heart failure related outcomes. Regardless, a high residual event rate is to be noted.
In our pilot study, we wished to document whether a clinical pharmacist could still play a role in the heart failure management of an elderly inpatient heart failure population.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 75 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •75 years or older
- •diagnosis of previous or new heart failure based on signs and symptoms as defined by the 'European Society of Cardiology guidelines on acute and chronic heart failure'
- •diagnosis had to be confirmed by a recent echocardiogram
排除标准
- •not Dutch speaking
- •treatment restrictions had been applied on admission
结局指标
主要结局
the number of heart-failure related pharmaceutical interventions
时间窗: during hospital stay (average of 14 days)
次要结局
- acceptance rate of the pharmaceutical interventions(during hospital stay (average of 14 days))
- clinical feasibility of the accepted interventions(during hospital stay (average of 14 days))
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
4 期
Carvedilol SR Study for Biomarkers From Blood and Urine and Safety of in Patients With Heart Failure With Preserved Ejection FractionHeart Failure With Preserved Ejection FractionNCT03948685Yonsei University300
终止
4 期
BOAT: Beta Blocker Uptitration With OptiVol After Cardiac Resynchronization Therapy (CRT)Congestive Heart FailureNCT00433043St. Luke's-Roosevelt Hospital Center2
已完成
1 期
A Study to Learn How the Study Treatment BAY1753011 Moves Into, Through and Out of the Body, How it Works, How Safe it is, and How it Affects the Body When Given Once as Tablet in Male and Female Participants With Reduced Kidney Function Compared to Matched Participants With Normal Kidney FunctionRenal ImpairmentCongestive Heart FailureNCT05599997Bayer32
Unknown
不适用
Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart FailureChronic Heart FailureNCT02282618Harbin Medical University180
已完成
1 期
A Trial to Learn How Safe Vericiguat (BAY1021189) is and the Way the Body Absorbs, Distributes and Gets Rid of Vericiguat in Participants With Liver Disease and in Age-, Weight- and Gender-matched Healthy ParticipantsHeart FailureNCT04722562Bayer27